Pharmasset

Did Gilead Sciences Make an $11 Billion Blunder?
Did Gilead Sciences Make an $11 Billion Blunder?
Motley Fool
Gilead Sciences
Pharmasset
hepatitis C
Flag link:
How Shrewd of a Dealmaker Is Gilead Sciences? Just Look at Its Last 7 Acquisitions
How Shrewd of a Dealmaker Is Gilead Sciences? Just Look at Its Last 7 Acquisitions
Motley Fool
Gilead Sciences
M&A
CV Therapeutics
CGI Pharma
Arresto Biosciences
Calistoga Pharmaceuticals
Pharmasset
YM BioSciences
EpiTherapeutics
Flag link:
A Look Back at 2 Successful Biotech Buyouts
A Look Back at 2 Successful Biotech Buyouts
Yahoo/GuruFocus
Gilead Sciences
Pharmasset
Merck
Idenix
M&A
Flag link:
Gilead Bets on Hepatitis C Data to Back Pharmasset Deal
Gilead Bets on Hepatitis C Data to Back Pharmasset Deal
Bloomberg
Gilead
hepatitis C
Pharmasset
BMS-790052
GS-7977
Flag link:
Hepatitis C Remains A Hot Play
Hepatitis C Remains A Hot Play
Seeking Alpha
hepatitis C
Bristol-Myers Squibb
Novartis
Gilead
Inhibitex
Merck
Vertex
Pharmasset
Enanta
Flag link:
Friday's Overreaction Provides Great Entry Point For Gilead
Friday's Overreaction Provides Great Entry Point For Gilead
Seeking Alpha
Gilead
Vertex
hepatitis C
Pharmasset
PSI-7977
Flag link:
Analyzing 5 Biotech Stocks And Their Takeover Potential
Analyzing 5 Biotech Stocks And Their Takeover Potential
Seeking Alpha
Abbott Laboratories
Achillion
Alexion
Bristol-Myers Squibb
Gilead
GSK
Human Genome Sciences
Indenix
Inhibitex
JNJ
Pfizer
Vertex
Pharmasset
Flag link:
Gilead nears completion of Pharmasset deal
Gilead nears completion of Pharmasset deal
Yahoo/AP
M&A
Pharmasset
Gilead
Flag link:
3 Reasons Hep C Premiums Might Not Last
3 Reasons Hep C Premiums Might Not Last
Motley Fool
hepatitis C
Anadys
Roche
Gilead
Pharmasset
Bristol-Myers Squibb
Inhibitex
Flag link:
A White Hot Hep C Market: What The Wags Say
A White Hot Hep C Market: What The Wags Say
Pharmalot
hepatitis C
Inhibitex
Bristol-Myers Squibb
Gilead
Pharmasset
M&A
Flag link:
Shares of hepatitis C drug developers rise on Bristol-Myers' $2.5B deal for Inhibitex
Shares of hepatitis C drug developers rise on Bristol-Myers' $2.5B deal for Inhibitex
Yahoo/AP
hepatitis C
Bristol-Myers Squibb
M&A
Inhibitex
Gilead
Pharmasset
Flag link:
Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period
Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period
Yahoo/BusinessWire
Gilead Sciences
Pharmasset
M&A
Flag link:
Pharmasset: M&A Presents Interesting Options Plays
Pharmasset: M&A Presents Interesting Options Plays
Seeking Alpha
M&A
Pharmasset
Gilead
Flag link:
Pharma winners of 2011 could keep surging next year
Pharma winners of 2011 could keep surging next year
Investorplace
Amgen
Biogen Idec
Celgene
Gilead
Pharmasset
Alexion
Regeneron
Flag link:
Biotech Stock Mailbag: Most Important Events for 2012
Biotech Stock Mailbag: Most Important Events for 2012
TheStreet.com
Oncothyreon
Keryx
Vical
Aeterna Zentaris
Eli Lilly
JNJ
Elan
Celgene
Pfizer
Gilead
Pharmasset
Threshold Pharmaceuticals
Celldex
Amgen
BioVex
Aveo Pharmaceutical
Amylin
Alkermes
Vertex
Cell Therapeutics
Amarin
ONYX Pharmaceuticals
Vivus
Flag link:
Health Care's Hottest Duo
Health Care's Hottest Duo
Motley Fool
Gilead
Pharmasset
hepatitis C
Achillion
Inhibitex
Flag link:
[video]4 Biotechs Dominating the Week
[video]4 Biotechs Dominating the Week
Motley Fool
YM BioSciences
BioSante
Pharmasset
Alexa
Flag link:
Five Drug Stock Winners of 2011
Five Drug Stock Winners of 2011
TheStreet.com
Inhibitex
Questcor
Medivation
Pharmasset
Pharmacyclics
Flag link:
Inhibitex, Idenix rattled by rival's drug failure
Inhibitex, Idenix rattled by rival's drug failure
MarketWatch
Inhibitex
Idenix
PSI-938
Pharmasset
hepatitis C
Flag link:
Hep C Drug Panic! Pharmasset Stumble Ripples Through Sector
Hep C Drug Panic! Pharmasset Stumble Ripples Through Sector
TheStreet.com
Pharmasset
hepatitis C
Gilead
Inhibitex
PSI-938
Indenix
Flag link:

Pages